Breaking
Trading Tech Trends
Author

admin

Browsing
Investing

Silverco Announces Upsizing of “Bought Deal” Offering to $62.5 Million

Investing 8 Mins Read

Silverco Mining Ltd. (TSXV: SICO,OTC:QTZCF) (‘Silverco’ or the ‘Company’) is pleased to announce that it has upsized its previously announced ‘bought deal’ offering (the ‘Offering’) with Velocity Capital Partners (‘Velocity’), as lead underwriter and sole bookrunner, on its own behalf and on behalf of a syndicate of underwriters (collectively, with Velocity, the ‘Underwriters’), from $40 million to $62.5 million.

Eric Sprott, a current insider of Silverco, will be participating in the Offering with a lead order of $10 million.

Pursuant to the upsizing, the Underwriters have agreed to purchase for resale, on a ‘bought deal’ basis, 4,000,000 common shares of the Company (the ‘Offered Shares‘) at a price of $12.50 (the ‘Issue Price‘) per Offered Share, for aggregate gross proceeds to the Company of $50 million.

In addition, the Offering will now also include the issuance of 1,000,000 units of the Company (the ‘Units‘ and together with the Offered Shares, the ‘Offered Securities‘) at the Issue Price per Unit, for additional aggregate gross proceeds to the Company of $12,500,000.

Each Unit will consist of one common share of the Company and one-quarter of one warrant, with each whole warrant being exercisable for one common share of the Company at an exercise price of $18.00 per share for a period of 18 months from the date of issuance.

The Offered Securities will be offered in each of the Provinces and Territories of Canada (other than Québec) as to: (i) the Offered Shares in reliance on the ‘listed issuer financing exemption’ from the prospectus requirements available under National Instrument 45-106 − Prospectus Exemptions (‘NI 45-106‘), as modified by Coordinated Blanket Order 45-935 – Exemptions from Certain Conditions of the Listed Issuer Financing Exemption (the ‘Listed Issuer Financing Exemption‘); and (ii) the Units in reliance on other exemptions from the prospectus requirements available under NI 45-106 other than the Listed Issuer Financing Exemption (the ‘Private Placement Exemption‘).

The Offered Securities may also be offered on a private placement basis in such offshore jurisdictions as may be mutually agreed between the Company and Velocity, provided it is understood that no prospectus filing or comparable obligation, ongoing reporting or continuous disclosure requirement or requisite regulatory or governmental approval arises in such jurisdictions, and in the United States pursuant to an exemption from the registration requirements of the United States Securities Act of 1933 (the ‘U.S. Securities Act‘), as amended. Any such Offered Securities will be characterized as ‘restricted securities’ under the U.S. Securities Act.

The net proceeds of the Offering will be used by the Company for exploration, evaluation and restart work on the Cusi Project, general and administrative expenditures and working capital.

The Offered Shares to be issued pursuant to the Listed Issuer Financing Exemption will not be subject to resale restrictions pursuant to applicable Canadian securities laws. The Units and any underlying securities to be issued pursuant to the Private Placement Exemption will be subject to a hold period of four months and one day from the Closing Date in accordance with applicable Canadian securities laws.

There is an amended and restated offering document related to the Offering that can be accessed on SEDAR+ (www.sedarplus.ca) under Silverco’s issuer profile and on the Company’s website at www.silvercomining.com. Prospective investors should read this amended and restated offering document before making an investment decision concerning the Offered Securities.

The Offering is expected to close on or about February 19, 2026 (the ‘Closing Date‘) and is subject to certain closing conditions including, but not limited to, the receipt of all necessary approvals including the conditional listing approval of the TSX Venture Exchange (‘TSXV‘) and the applicable securities regulatory authorities. The Offering is subject to final acceptance of the TSXV.

The Offered Securities have not been registered and will not be registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements. This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any State in which such offer, solicitation or sale would be unlawful.

About Silverco Mining Ltd.

The Company owns a 100% interest in the 11,665-hectare Cusi Project located in Chihuahua State, Mexico (the ‘Cusi Property‘). It lies within the prolific Sierra Madre Occidental gold-silver belt.There is an existing 1,200 ton per day mill with tailings capacity at the Cusi Property.

The Cusi Property is a past-producing underground silver-lead-zinc-gold project approximately 135 kilometres west of Chihuahua City. The Cusi Property boasts excellent infrastructure, including paved highway access and connection to the national power grid.

The Cusi Property hosts multiple historical Ag-Au-Pb-Zn producing mines each developed along multiple vein structures. The Cusi Property hosts several significant exploration targets, including the extension of a newly identified downthrown mineralized geological block and additional potential through claim consolidation.

On Behalf of the Board of Directors,

Mark Ayranto, President & CEO
Email: mayranto@silvercomining.com
Phone: 778-888-4010

For further information, please contact:
Investor Relations & Communications
Email: info@silvercomining.com
www.silvercomining.com

Cautionary Statement and Forward-Looking Information

This news release contains ‘forward-looking statements’ within the meaning of the applicable Canadian securities legislation that are based on expectations, estimates, assumptions, geological theories, and projections as at the date of this news release. The information in this news release about any information herein that is not a historical fact may be ‘forward-looking statements.’ Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (which may, but not always, include phrases such as ‘anticipates’, ‘plans’, ‘scheduled’, ‘believed’ or ‘intends’ or variations of such words and phrases or stating that certain actions, events or results ‘may’ or ‘could’, ‘would’, ‘might’ or ‘will’ be taken to occur or be achieved) including statements regarding the Company’s plans with respect to the Company’s projects and the timing related thereto, the merits of the Company’s projects, the Company’s objectives, plans and strategies, the Offering, the listing of the Common Shares on the TSXV, the use of proceeds of the Offering and other matters are not statements of historical fact and may be forward-looking statements and are intended to identify forward-looking statements.

Although the forward-looking statements contained in this news release are based upon what management believes, or believed at the time, to be reasonable assumptions, the Company cannot assure readers that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Such factors include, among others, with respect to the Offering, the conditions of the financial markets, timeliness of completion of the Offering, and the timing of TSXV approval; and with respect to the use of proceeds, the availability of drills and personnel, weather, the speculative nature of mineral exploration and development, fluctuating commodity prices, risks relating to the timing and ability of the Company to obtain and the timing of the approval of relevant regulatory bodies, if at all; risks relating to property interests; risks related to access to the project; risks inherent in mineral exploration, including the fact that any particular phase of exploration may be unsuccessful; the availability of contractors; geo-political risks; the global economic climate; metal prices; environmental risks; political risks; and community and non-governmental actions, as described in more detail in our recent securities filings available on SEDAR+ (www.sedarplus.ca) under Silverco’s issuer profile. Further to this, geological similarities or characteristics are not guarantees or certainties of successful exploration. Neither the Company nor any other person assumes responsibility for the accuracy and completeness of any such forward-looking statements. Accordingly, readers should not place undue reliance on forward-looking statements. When considering this forward-looking information, readers should keep in mind the risk factors and other cautionary statements in the Company’s disclosure documents filed with the applicable Canadian securities regulatory authorities on SEDAR+ (www.sedarplus.ca) under Silverco’s issuer profile. The risk factors and other factors noted in the disclosure documents could cause actual events or results to differ materially from those described in any forward-looking information. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Not for distribution to United States newswire services or for dissemination in the United States

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/282065

News Provided by TMX Newsfile via QuoteMedia

This post appeared first on investingnews.com

Keep Reading
Investing

Willem Middelkoop: Silver Short Squeeze Not Over, Get Ready for Metal Wars

Investing 1 Min Read

Willem Middelkoop, founder of Commodity Discovery Fund, breaks down his outlook for silver, saying that at this point US$200 or even US$300 per ounce is in the cards for the white metal.

‘We’re in the first innings I think of this short squeeze, so it’s not over yet,’ he said.

Securities Disclosure: I, Charlotte McLeod, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

Keep Reading
Investing

Silicon-Driven Health: AI Digital Twins and the US$1 Billion Pharma Deal

Investing 7 Mins Read

As massive capital flows into the life science sector, two distinct, and potentially opposing, strategic directions have emerged.

While NVIDIA (NASDAQ:NVDA) is expanding its healthcare presence through a US$1 billion deal with Eli Lilly and Company (NYSE:LLY), Twin Health’s metabolic AI uses digital twins alongside device-driven biometrics to reverse chronic disease, a shift with the potential to render some medications, including high-cost GLP-1s, unnecessary.

This convergence of physical AI and digital twin technology marks a new era where silicon meets biology.

The digital twin: From concept to US$1 billion reality

Dr. Michael Grieves first introduced the conceptual model of digital twins at a Society of Manufacturing Engineers conference in Michigan in 2002. He originally called it the “Information Mirroring Model”.

The phrase was coined by NASA technologist John Vickers in 2010. He was collaborating with Dr. Grieves and suggested the name for a NASA technical roadmap to describe the virtual replicas of spacecraft used for simulation and safety.

NVIDIA CEO Jensen Huang is currently the concept’s most well-known advocate after he used it to describe a cornerstone of NVIDIA’s Omniverse and industrial AI strategy at the GTC 2021 keynote. He later expanded this vision at CES 2026, where he declared that “the future of heavy industries starts as a digital twin.”

In a move that expands digital twins’ use cases, NVIDIA and Eli Lilly recently announced a first-of-its-kind, five-year partnership to build a co-innovation lab in the San Francisco Bay Area. This US$1 billion investment focuses on moving drug discovery away from traditional trial-and-error toward a high-speed engineering model.

Under the terms of the collaboration, the lab will utilize NVIDIA’s Vera Rubin chips, the successor to the Blackwell architecture, to provide the massive computational power required for large-scale biological models.

Researchers will use NVIDIA’s BioNeMo AI platform to simulate vast chemical and biological spaces in silico before a single physical molecule is created in a lab.

The collaboration extends into manufacturing, using NVIDIA Omniverse to create digital twins of production lines. This allows Lilly to stress-test supply chains and optimize the manufacturing of high-demand medications, such as GLP-1s and next-generation weight loss drugs.

Twin Health: Reversing chronic disease with digital twins

While NVIDIA and Lilly focus on creating new drugs, Twin Health is using AI to help patients wean off chronic injections.

Twin Health is a precision health company focused on reversing chronic metabolic diseases, specifically type 2 diabetes and related conditions like obesity and hypertension, using AI and digital twin technology. The company was founded by Jahangir Mohammed, a serial entrepreneur who previously founded Jasper, an Internet of Things (IoT) pioneer, which was later acquired by Cisco.

The core of Twin Health’s whole body digital twin technology is creating a dynamic, virtual map of a patient’s unique metabolism by gathering over 3,000 daily data points, including blood sugar, heart rate, sleep and physical activity.

Users wear continuous glucose monitors and smartwatches at home to capture real-time data, paired with a provided smart scale and blood pressure cuff for daily vitals. AI takes this data to build a digital replica of the user’s body’s unique metabolic responses.

No routine clinic visits are required for data collection, though periodic lab work and tele-coaching support the program. Through a mobile app, the AI provides real-time nudges; for example, it might tell the wearer that a 15-minute walk now will stabilize a blood sugar spike from their lunch.

On January 12, the company rang the Nasdaq opening bell as new clinical and economic data were released that highlighted the platform’s efficacy in high-cost patient populations. Central to this milestone was the Cleveland Clinic-led Randomized Controlled Trial (RCT), originally published in the New England Journal of Medicine Catalyst on August 20, 2025.

The study demonstrated that 71 percent of participants achieved type 2 diabetes reversal, defined as a level of hemoglobin A1C below 6.5 without the use of insulin or other glucose-lowering medications, with the exception of metformin, a low-cost, common first-line drug. Crucially for today’s market, the data showed that 85 percent of users were able to eliminate high-cost GLP-1 medications, such as Ozempic and Wegovy, while maintaining optimal blood sugar levels.

Market analysis: The payer revolt and the shift to value

The GLP-1 drug class rapidly transitioned from niche diabetes medications to multi-billion dollar blockbusters for obesity. From 2018 to 2023, researchers found that spending on GLP-1s in the US rose by more than 500 percent to reach US$71.7 billion. Sales are projected to reach US$100 billion by 2030.

In a fierce race to meet skyrocketing demand that outstripped production capacity, Eli Lilly and its main competitor in this space, Novo Nordisk (NYSE:NVO), committed massive investments. Lilly invested US$9 billion into API production, while Novo Nordisk matched this with a US$11 billion investment in facilities across Denmark and North Carolina.

Now, both companies are chasing affordability via direct-to-consumer deals and 2026 oral pills as payers raise plan costs or restrict access. AON’s Global Medical Trend Rates Report for 2026 projects 9.8 percent hikes in employer plan costs from GLP-1s and utilization surges, as Mercer’s Survey on Health and Benefit Strategies for 2026 shows 77 percent of large employers targeting GLP-1 costs, with coverage growth stalling amid restrictions.

The payer revolt is fueling Twin Health’s rise, marked by its US$53 million August 2025 raise for Fortune 500 expansion. Twin Health’s performance model pays on outcomes, delivering an estimated US$8,000 savings per high-cost member.

Big Pharma is betting on AI not just to sustain blockbuster growth but to reinvent the discovery engine amid exploding development costs. At Davos, Nvidia CEO Jensen Huang illustrated this shift bluntly: “Three years ago, most of their R&D budget…was probably wet labs,” Huang said. “Notice the big AI supercomputer that they’ve invested in, the big AI lab. Increasingly, that R&D budget is going to shift towards AI.”

This comes as the pharmaceutical sector comes under pressure to justify hundreds of billions in R&D spending, where Phase I candidates still face a roughly 90 percent failure rate before approval. Eli Lilly could lower the cost of drug failure by embedding NVIDIA’s Vera Rubin chips into a 24/7 learning loop.

The divergence between NVIDIA’s pharmaceutical supercomputer and Twin Health’s metabolic reversal tech captures 2026’s market trend pivot from AI experimentation to proven ROI. Deloitte’s 2026 US Health Care Outlook emphasizes that the industry is moving away from theoretical models in favor of scaling AI to realize measurable financial impact.

Investor outlook

Payers requiring measurable ROI are pushing healthcare innovators to prove value, whether by improving drug discovery or reversing chronic disease.

This tension shapes investment strategies, too. Paul MacDonald, CIO at Harvest ETFs, welcomes AI’s momentum while highlighting GLP-1’s staying power in the firm’s HHL ETF.

“AI in healthcare is very exciting, and we see practicable applications being deployed across many fields, most notably in the diagnostics areas, but increasingly in biopharma research and medical devices.

“As exciting as technology like wearables and designing more personalized lifestyle plans is, we continue to believe that the broader obesity drug classes and markets will continue to grow significantly in the coming years.

MacDonald points to expanding Medicare access and oral formulations as key drivers, even as payers tighten restrictions.

“The systemic benefits and significant health benefits beyond weight loss from the drugs (are) resulting in expanding adoption, and broader coverage affording larger patient cohorts to access the drugs. Currently, there are pilot plans to expand access for Medicare (enrollees) in the USA later this year, which (will expand) the prescription volume potential significantly.

“In addition to the traditional subcutaneous injection, oral options are increasing in availability, and that not only increases the potential for broader adoption but also improves the overall cost structure and margins for the companies with established production facilities.”

MacDonald’s balanced allocation of AI excitement alongside GLP-1 conviction captures a new reality: in 2026, life sciences investors are navigating a complex landscape defined by more variables than ever before.

Securities Disclosure: I, Meagen Seatter, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

Keep Reading
Investing

Don Durrett: Gold, Silver Prices Going Higher, Watch These Stocks

Investing 1 Min Read

Don Durrett of GoldStockData.com explains why gold’s record-setting price run isn’t over.

‘The reason gold is at US$5,000 (per ounce) and going higher is because the US bond market is fragile and becoming more fragile every day,’ he said. ‘But not only that — I’ve said this — it’s going to fail, and that’s why gold keeps going higher and higher and higher.’

Securities Disclosure: I, Charlotte McLeod, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

Keep Reading
Investing

Harvest Gold Discovers Significant Gold-Silver-Copper Halos In The Northern Part Of The Mosseau Property

Investing 7 Mins Read

(TheNewswire)

 

Vancouver, British Columbia / January 29, 2026 ‑ TheNewswire – Harvest Gold Corporation (TSXV: HVG,OTC:HVGDF) (‘Harvest Gold‘ or the ‘Company‘) is pleased to announce the results of a detailed review of current and historical drilling data conducted in light of the Company’s 2025 drilling program.  This work has identified several significant near-surface Au-Ag-Cu halos in the northern portion of the Mosseau Property, its flagship property in the Urban Barry Belt in Quebec’s Abitibi region.

Rick Mark, President and CEO of Harvest Gold, stated: ‘Our most recent press release announced, among other things, 10 and 19-meter widths of anomalous gold or copper at depth below the historic, non 43-101 Morono gold deposit. We realized we had identified something new, forty plus years after the last Morono drill program. We also realized samples were not analysed for copper and silver during historic drilling. That led our Geological team to evaluate the historical data of the entire North area of Mosseau. This new understanding of the area’s mineralization changed our thinking.’

Louis Martin, geologist for Harvest Gold in Quebec states: ‘The identification of broad, near-surface gold with Ag-Cu pathfinders from historical drilling significantly strengthens the interpretation of our 2025 drill results. Re-evaluating the Mosseau data using this model continues to improve our understanding of the mineralizing system and provides a strong technical basis for targeting and additional drilling in the northern part of the property.’

Following the reporting of wide gold intersections with associated anomalous silver and copper from the 2025 drill program (see Harvest Gold press releases dated January 8, 2026), the Company initiated a systematic re-evaluation of historical drill results to identify similar styles of mineralization. This review applied a lower gold cut-off grade than used by previous operators to better define broad zones of mineralization consistent with the Au and Ag-Cu pathfinders recognized in the Harvest Gold 2025 drilling.

As a result of this new analytical perspective, multiple significant Au-Ag-Cu halos have been identified within several key target areas on the Mosseau Property.  Critically, this allows the Company to narrow its focus to three principal areas of interest, including Trench #1, the Morono Gold Deposit, and what were thought to be isolated targets along the northern boundary of the property (see Figure 1, Figure 2).

Examples of broad Au-Ag-Cu halos from holes drilled by SOQUEM in 2001 (GM59164) in the area of Trench #1 include:

  • 1.44 g/t Au over 26.2 metres (hole 1217-01-13) 

  • 3.37 g/t Au over 14.1 metres (hole 1217-01-14) 

Both drill holes also returned anomalous silver and copper values directly associated with the higher-grade gold intervals, similar to the results observed in the 2025 drilling by Harvest Gold (see Table 1).

At the Morono Gold Deposit, several wide historical intersections—locally extending up to 35.36 metres—further illustrate the potential for extensive gold halo development. Selected historical intersections include:

  • 3.84 g/t Au over 8.4 metres (M-4-88) 

  • 3.05 g/t Au over 7.62 metres (M-12-87) 

  • 2.66 g/t Au over 8.35 metres (M-25-87). 

Importantly, most of these historical intercepts occur at shallow depths and near surface, highlighting the potential for bulk-tonnage and open-pit style mineralization, subject to additional drilling and future economic studies.

Based on these results, Harvest Gold has expanded its understanding of the Northern area of Mosseau and believes it now generates an expanded opportunity and is contemplating a follow-up drill program in the northern portion of the Mosseau Property. The proposed program would consider up to 40 diamond drill holes totalling up to 6,000 metres to further test and expand these newly discovered Au-Ag-Cu halo zones.

About Harvest Gold Corporation

Harvest Gold is focused on exploring for near-surface gold deposits and copper-gold porphyry deposits in politically stable mining jurisdictions. Harvest Gold’s board of directors, management team and technical advisors have collective geological and financing experience exceeding 400 years.

Harvest Gold has three active gold projects focused in the Urban Barry area, totalling 377 claims covering 20,016.87 ha, located approximately 45-70 km west of Gold Fields Limited’s – Windfall Deposit (Figure 3).

Harvest Gold acknowledges that the Mosseau Gold Project straddles the Eeyou Istchee-James Bay and Abitibi territories.  Harvest Gold is committed to developing positive and mutually beneficial relationships based on respect and transparency with local Indigenous communities.

Harvest Gold’s three properties, Mosseau, Urban-Barry and LaBelle, together cover over 50 km of favorable strike along mineralized shear zones.


Click Image To View Full Size 

Figure 1: Northern part of Mosseau showing gold halos (metal factor)

 


Click Image To View Full Size 

Figure 2: Northern part of Mosseau showing gold halos (metal factor) on magnetics

  

Table 1: Historical drill hole intersections with anomalous Au halos

Hole-ID

From (m)

To (m)

Length

Au (gpt)

1217-01-14

33.50

47.60

14.10

3.37

1217-01-13

26.60

52.80

26.20

1.44

M-4-88

308.31

317.14

8.84

3.84

M-12-87

87.48

95.10

7.62

3.05

M-25-87

69.01

77.36

8.35

2.66

M-26-87

49.38

74.98

25.60

0.72

MO-17-10

39.00

57.00

18.00

1.00

1217-20-47

120.00

125.50

5.50

2.96

M-40-87

153.68

172.88

19.20

0.81

M-46-87

51.97

87.33

35.36

0.44

M-7-87

68.43

82.36

13.93

1.06

1217-18-34

45.20

59.50

14.30

1.03

M-32-87

124.05

147.52

23.47

0.59

M-68-87

224.03

245.36

21.34

0.62

1217-18-35

58.00

63.20

5.20

2.53

1217-20-45

157.50

196.50

39.00

0.33

M32-87

124.10

147.50

23.40

0.54

M-5-88

263.35

283.16

19.81

0.61

M-24-87

49.35

56.66

7.32

1.64

M-27-87

73.88

82.02

8.14

1.45

M-16b-87

109.00

136.25

27.25

0.43

M-43-87

137.16

151.33

14.17

0.81

M-28-87

62.73

78.27

15.54

0.74

M-4-87

84.70

99.97

15.27

0.71

M28-87

62.70

78.30

15.60

0.67

M-45-87

49.93

64.68

14.75

0.69

M33-87

116.10

137.30

21.20

0.46

M-13-87

80.99

87.08

6.10

1.59

Reported intervals are drilled core lengths (true widths have not yet been determined)

 


Click Image To View Full Size 

Figure 3: Project Location: Urban-Barry Greenstone Belt

  

NI 43-101 Disclosure – Historical Data

The historical drill results referenced in this news release were completed by previous operators and have not been independently verified by Harvest Gold Corporation. Although the Company considers the historical work to be relevant and reliable, it has not completed sufficient work to verify these historical results and does not rely on them for the purposes of this disclosure. The historical information is presented solely to provide context for current exploration results and ongoing exploration planning.

 

Qualified Person Statement

All scientific and technical information in this news release has been prepared and approved by Louis Martin, P.Geo., Technical Advisor to the Company and considered a Qualified Person for the purposes of NI 43-101.

ON BEHALF OF THE BOARD OF DIRECTORS

Rick Mark
President and CEO
Harvest Gold Corporation

For more information please contact:

Rick Mark or Jan Urata
@ 604.737.2303 or info@harvestgoldcorp.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward Looking Information

This news release includes certain statements that may be deemed ‘forward looking statements’. All statements in this news release, other than statements of historical facts, that address events or developments that Harvest Gold expects to occur, are forward looking statements. Forward looking statements are statements that are not historical facts and are generally, but not always, identified by the words ‘expects’, ‘plans’, ‘anticipates’, ‘believes’, ‘intends’, ‘estimates’, ‘projects’, ‘potential’ and similar expressions, or that events or conditions ‘will’, ‘would’, ‘may’, ‘could’ or ‘should’ occur.

Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward looking statements include market prices, exploitation and exploration successes, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward looking statements are based on the beliefs, estimates and opinions of the Company’s management on the date the statements are made. Except as required by securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management’s beliefs, estimates or opinions, or other factors, should change.

Copyright (c) 2026 TheNewswire – All rights reserved.

News Provided by TheNewsWire via QuoteMedia

This post appeared first on investingnews.com

Keep Reading
Investing

Seegnal Presents Real-World Evidence on Reducing Fall Risk in Geriatric Patients at Caltcm Summit

Investing 7 Mins Read

Seegnal Inc. (TSXV: SEGN) (‘Seegnal‘ or the ‘Corporation‘), a global leader in AI-enhanced prescription intelligence, today announced real-world clinical results demonstrating how medication governance may reduce fall-risk drivers in older adults — a significant clinical and financial challenge across long-term care (LTC), and risk-based care models.

The findings, presented at the CALTCM Summit for Excellence (October 23–25, 2025), provide direct evidence that prescribing decisions — when measured and governed at scale — represent one of the largest untapped levers for cost avoidance and quality improvement in senior care.

A DIRECT HIT ON ONE OF LTC’S MOST EXPENSIVE PROBLEMS

Falls are a significant cause of hospitalization, litigation exposure, staffing strain, and avoidable costs in LTC facilities.

Seegnal analyzed real-world prescribing behavior related to alpha-blocker use in older women, a known contributor to falls, using live clinical workflows rather than retrospective claims data.

The study population included 124,461 female patients aged 70 or older

Results from a three-month deployment:

  • 5,088 real prescribing alerts analyzed
  • 35% of cases resulted in treatment modification (~1,750 patients)
  • High rates of temporary and repeated overrides, signaling systemic risk patterns rather than one-off clinical judgment

The implication for LTC operators is clear: fall risk is being created upstream at the prescription level — and can be mitigated before it becomes an admission, incident report, or lawsuit.

WHY THIS MATTERS FOR PAYERS AND LONG-TERM CARE NETWORKS

Unlike traditional clinical decision support tools that fire alerts and stop there, Seegnal exposes how organizations actually prescribe, where risk accumulates, and where policy gaps exist.

For LTC operators and payers, this enables:

  • Reduction in fall-related hospitalizations.
  • Lower pharmacy spends and medication burden.
  • Improved quality metrics and star ratings.
  • Meaningful risk reduction without workflow disruption.
  • Actionable data to support value-based contracts.

The results of the study are encouraging as they demonstrate the possibility of cost avoidance + capacity creation driven by real prescribing behavior.

FROM ALERTS TO PRESCRIPTION GOVERNANCE

The CALTCM findings highlight a broader structural issue in senior care: clinicians often recognize medication risk, but organizations often lack the governance layer to turn that insight into sustained, system-wide improvement.

Seegnal aims to fill that gap by acting as the Prescription Operating System for healthcare organizations — enabling them to:

  • Track prescribing risk across facilities and populations.
  • Distinguish justified clinical exceptions from unsafe patterns.
  • Set, monitor, and refine medication policies at scale.
  • Align clinical safety with financial accountability.

MANAGEMENT COMMENTARY

‘In long-term care, falls are not just clinical events — they are balance-sheet events,’ said Elad Bibi-Aviv, Chief Executive Officer of Seegnal.

‘What this data shows is that prescribing decisions are one of the few levers organizations can control before costs explode. Seegnal gives LTC operators and payers visibility and control where it actually matters — upstream.’

‘Organizations don’t need more alerts. They need governance, measurement, and proof of value. That is exactly what Seegnal was built to deliver.’

‘Technology is essential, but the real impact on patient outcomes depends on implementation and culture. Seegnal not only integrates seamlessly into workflows but also flags non-rational medication use at the institutional level, enabling management to drive clinical excellence,’ said Dr. Shiri Guy-Alfandary, VP Clinical & Product.

BUILT FOR THE LONG-TERM CARE MARKET: DATA FIRST, FAST VALUE

Seegnal is actively opening Long Term Care engagements through a data-first model:

  • Read-only clinical data access (no workflow change).
  • Rapid identification of high-cost prescribing patterns.
  • Clear clinical and economic KPIs.
  • Scalable deployment once value is proven.

This approach aligns directly with the needs of:

  • Multi-facility LTC operators.
  • Payers.
  • Risk-bearing provider networks.

ABOUT THE CLINICAL EVIDENCE

The findings were presented in ‘Reducing Inappropriate Use of Alpha-blockers in Geriatric Patients’ by Dr. Hen Popilski and Dr. Shiri Guy-Alfandary, PharmD, Seegnal, based on real-world prescribing data from routine clinical practice.

The findings and conclusions referenced in this press release are derived from Seegnal’s internal studies. These findings are preliminary in nature, may be based on assumptions and methodologies developed for internal use, and have not been independently audited, verified, or peer‑reviewed. The information is provided solely for general informational purposes.

About Seegnal

Seegnal is a public company that aims to solve one of the top causes of death and injuries in the modern world – Adverse Drug Effects (ADEs). Seegnal’s Clinical Decision Support system introduces a paradigm shift in the approach to this problem by implementing a new elevated Patient-Centric Standard. Seegnal’s SaaS technology exclusively integrates, at the point-of-care, unique patient-specific data such as lab results, vital signs, ECG, smoking status, allergies, food interactions, gender, age, and the effects of many concomitant medications, while reducing the current alert load for clinicians by over 90%. In practice, clinicians using Seegnal eHealth complete their prescription workflow with limited interruption, saving time and fatigue. Patients enjoy more tailored medication and improved safety, leading to better quality of life, with precision alerts reaching up to 98% accuracy. Institutions have reported reductions in admissions, medication consumption, and significant time savings in prescription renewals. Seegnal eHealth is marketing its SaaS-based platform in Israel (where the Ministry of Health recently adopted Seegnal’s patient-specific standard as the new standard in governmental hospitals), the United Arab Emirates, the United Kingdom, the United States, and Poland. The platform is currently a ‘standard of care’ system for over 15,000 clinicians in Israel, used daily for prescribing medications.

See www.seegnal.com.

Cautionary Note Regarding Forward-Looking Information

This press release contains ‘forward-looking information’ or ‘forward-looking statements’ within the meaning of Canadian securities legislation. All statements included herein, other than statements of historical fact, including statements included in the ‘About Seegnal’ section of this press release, are forward-looking. Generally, the forward-looking information and forward-looking statements can be identified by the use of forward-looking terminology such as ‘anticipate’, ‘believes’, ‘estimates’, ‘expects’, ‘intends’, ‘may’, ‘should’, ‘will’ or variations of such words or similar expressions. More particularly, and without limitation, this press release contains forward-looking information or forward-looking statements concerning the application of Seegnal’s findings and conclusions, and any benefit, implied or express, that may be realized by Seegnal or its clients. These statements, including the findings discussed herein, are based on current assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. Please refer to Seegnal’s public filings with applicable securities regulators for additional information regarding risk factors and other disclosures.

Seegnal cautions that all forward-looking information and forward-looking statements are inherently uncertain, and that actual performance may be affected by a number of material factors, assumptions and expectations, many of which are beyond the control of Seegnal, including expectations and assumptions concerning Seegnal and its products as well as other risks and uncertainties, including those described in Seegnal’s filings available on SEDAR+ at www.sedarplus.ca. The reader is cautioned that assumptions used in the preparation of any forward-looking information or forward-looking statements may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted as a result of numerous known and unknown risks, uncertainties and other factors, many of which are beyond the control of Seegnal. The reader is cautioned not to place undue reliance on any forward-looking information or forward-looking statements. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking information and forward-looking statements contained in this press release are expressly qualified by this cautionary statement.

The forward-looking information and forward-looking statements contained in this press release are made as of the date of this press release, and Seegnal does not undertake any obligation to update publicly or to revise any of the included forward-looking information or forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by law.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Source

This post appeared first on investingnews.com

Keep Reading
Investing

Gold Price Breaks Above US$5,300 as Fed Holds Rates Steady

Investing 5 Mins Read

The US Federal Reserve held its first meeting of 2026 from Tuesday (January 27) to Wednesday (January 28) amid growing tensions between Fed independence and the Trump administration.

The central bank met analysts’ expectations by maintaining the federal funds rate in the 3.5 to 3.75 percent range. After three consecutive cuts at the end of 2025, the Fed decided to hold the line on interest rates. The board welcomed some positive signs of stabilization in the US economy, but has decided to take a “wait-and-see” approach.

The Fed has a dual mandate to promote maximum employment and price stability.

For several months now, its Board of Governors has been split between those concerned with preventing a further slowdown in the US labor market and those fearing the fight against inflation is far from over.

The Fed’s preferred inflation metric, the Personal Consumption Expenditures (PCE) price index, came in above the 2 percent target, landing at 2.8 percent for November 2025. Meanwhile, Bureau of Labor Statistics data shows that the US economy added a modest 50,000 jobs in December 2025 compared to 56,000 jobs added in the previous month.

A weak labor market in the face of entrenched inflation has left the Fed in a pickle.

Lowering rates in turn lowers the cost of borrowing, which can provide businesses with more runway to grow their workforce. However, increasing available money supply by easing access to borrowing can also increase inflation.

The split between doves and hawks that began in late 2025 is still plaguing the Fed into the new year, which promises to see current Chair Jerome Powell replaced with someone more likely to be on board with the much lower rate environment desired by the Trump administration. Two Fed board members cast dissenting votes against holding rates steady, including Governor Stephen Miran and Governor Christopher Waller, who both pushed for a 0.25 percent cut.

“Economic activity has been expanding at a solid pace,” explained the Fed. “Job gains have remained low, and the unemployment rate has shown some signs of stabilization. Inflation remains somewhat elevated.”

The unemployment rate ended 2025 at 4.4 percent. While that’s historically low, data also shows limited job vacancies, and low rates of new hiring. Business Insider reporter Madison Hoff notes that economists are calling this a “low-fire, low-hire environment” due to uncertainty over where the economy is headed.

“It’s likely Fed leaders will stick to the status quo in January, in hopes that steady rates will push inflation closer to their 2% goal,” she wrote. “Affordability is a major concern for American households, as prices rise on housing, groceries, healthcare, and more. Powell has consistently prioritized price stability during his time as chair.”

During a press conference following the rate decision, Powell was careful not to commit to any future rate cut timeline. While the board still sees “some tension between employment and inflation,” that is moderating, and the Fed no longer sees any big risk either of accelerated inflation or a further significant breakdown in the labor market.

There’s also not much chance of a rate hike, either.

“We don’t take things off the table, but it isn’t anybody’s base case right now,” said Powell.

While PCE remains elevated at 2.8 percent, Powell noted that if the impact of tariffs were removed that figure would be hovering just above 2 percent. He explained that the Fed thinks this impact is largely in the rear-view mirror now.

Any day now, US President Donald Trump is expected to announce a replacement for Powell, whose term expires in May 2026. Trump has criticized the Fed and Powell in particular, saying they haven’t lowered rates quickly enough.

On October 27, US Secretary of the Treasury Scott Bessent announced a shortlist of candidates to replace Powell, including Fed governors Christopher Waller and Michelle Bowman, National Economic Council Director Kevin Hassett, former Fed Governor Kevin Warsh and BlackRock (NYSE:BLK) executive Rick Rieder.

The Wall Street heavyweight is reportedly the favored candidate at the moment.

“Under Warsh, the Fed would likely signal a preference for a smaller footprint. Despite recent support for near-term rate cuts, his longer-standing views favor a scarce-reserves framework and balance-sheet reduction, which markets would associate with higher term premium and greater yield-curve volatility,” he added.

Trump’s feud with the Fed escalated earlier this month, when the US Department of Justice served the agency with grand jury subpoenas, threatening a criminal indictment over Powell’s testimony to the Senate Banking Committee this past June. In addition to that, last week, the Supreme Court sat for oral arguments over whether Trump can legally remove Fed Governor Lisa Cook from her position over allegations of mortgage fraud.

Although Powell batted away any political questions from reporters during the press conference, he did acknowledge that the Supreme Court case between Trump and Cook is the most “important legal case in the Fed’s 113-year history.’

The gold price spiked to a new high of US$5,361.31 per ounce after the Fed’s decision, although much of that boost likely came from a much weaker US dollar, which is trading at four year lows. Silver traded in a range of US$110 to US$116 per ounce, just below the all-time high of US$117.72 per ounce set on Monday (January 26).

Equities reactions were fairly muted following the rate announcement on Wednesday, with the S&P 500 (INDEXSP:INX) up 0.083 percent to reach 6,972.78. Meanwhile, the Nasdaq-100 (INDEXNASDAQ:NDX) gained 0.31 percent to come in at 26,020.9, and the Dow Jones Industrial Average (INDEXDJX:DJI) was down 0.0064 percent, coming to 49,000.29. It seems Wall Street had already factored in the Fed’s decision to hold.

The next Fed interest rate decision will come on March 18, the second to last Fed meeting before Powell’s term as chair comes to an end. Most analysts expect interest rates to remain in a holding pattern until the second half of 2026.

Securities Disclosure: I, Melissa Pistilli, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

Keep Reading
Investing

4 Platinum Uses for Investors to Know

Investing 6 Mins Read

Platinum may be rare, but it is the third most-traded precious metal in the world, behind gold and silver.

The world’s platinum demand varies widely across many sectors. Most notably, platinum metal is used in autocatalysts and jewelry, as well as for medical and industrial purposes. Those interested in investing in platinum would do well to be aware of the many platinum uses. After all, by knowing which industries require platinum, it’s possible to understand supply and demand dynamics, and to be aware of how the precious metal’s price may move in the future.

With that in mind, here’s a list of the four main platinum uses. Scroll on to learn more about platinum’s key applications.

In this article

    1. Autocatalysts

    One of the main platinum uses is in the construction of autocatalysts. An autocatalyst is a “cylinder of circular or elliptical cross section made from ceramic or metal formed into a fine honeycomb and coated with a solution of chemicals and platinum group metals.” An autocatalyst mounted inside a stainless steel canister is known as a catalytic converter.

    Catalytic converters are installed in a vehicle’s exhaust lines, between the engine and muffler, where they are used to moderate the dangerous qualities of exhaust. Specifically, the autocatalysts that vehicles contain convert over 90 percent of hydrocarbons and carbon monoxide into carbon dioxide, nitrogen and water vapor. They can also convert pollutants from diesel exhaust into carbon dioxide and water vapor, which is immensely helpful in reducing pollution.

    Autocatalysts have been used in the US and Japan since 1974, and are now so common that over 95 percent of new vehicles sold each year have one. As a result, they are a significant source of platinum demand that is not likely to disappear in the future. Indeed, as pollution rules become more stringent, car companies are looking at creating even more efficient autocatalysts.

    According to data from the World Platinum Investment Council (WPIC), automotive demand is forecasted to fall 3 percent to 3.02 million ounces in 2025 before falling another 3 percent to 2.92 million ounces in 2026.

    2. Platinum jewelry

    Platinum has many qualities that make it ideal for use in jewelry, and that is the second largest source of platinum demand. The metal is strong, resists tarnish and can repeatedly be heated and cooled without hardening or oxidizing.

    When used to make jewelry, platinum is commonly alloyed with other platinum-group metals such as palladium, as well as copper and cobalt, so that it is easier to work with.

    The history of platinum jewelry is long. More than 2,000 years ago, Indigenous people in South America made rings and ornaments out of platinum. Egyptians used platinum for decoration as early as the 7th century BCE. Meanwhile, Europeans began to use the metal in jewelry in the 18th century. Currently, China is the largest market for platinum jewelry.

    The WPIC expected platinum demand for jewelry was expected to increase 7 percent year-over-year to 2.16 million ounces in 2025, then decline 6 percent in 2026 to 2.04 million ounces.

    3. Industrial applications

    Platinum’s industrial applications could fill a book all on their own. For instance, platinum catalysts are used to manufacture fertilizer ingredients, and the metal is a key component in silicones, hard disks, electronics, dental restoration, glass-manufacturing equipment and sensors in home safety devices.

    Another platinum use is in the construction of hard drives with extremely high storage densities. And, because it is reactive to oxygen, oxides of nitrogen and carbon monoxide, platinum can be used to detect changes in the amount of those materials in vehicles and buildings. For the same reason, platinum is also used in medical sensors, particularly medical instruments that measure blood gases, to detect oxygen.

    Among growing segments is platinum’s use as a catalyst in the production of green hydrogen. Similar to how the metal is used to convert automotive pollutants, it can also be used as an electrolyzer to convert water into hydrogen and oxygen, with the resulting hydrogen usable in emission-free fuel cell vehicles. In 2025, demand from hydrogen production is predicted to grow by 20 percent to 50 million ounces, then increasing another 36 percent in 2026 to 58,000 ounces.

    Overall, WPIC forecast that industrial demand for platinum, including medical demand, would fall 22 percent to 1.9 million ounces in 2025 before growing 9 percent to 2.08 million ounces in 2026.

    4. Medical applications

    Platinum is used in electronic medical devices like those mentioned above, as well as in catheters, stents and neuromodulation devices. It is ideal for these applications because of its durability, conductivity and biocompatibility. The metal is also inert within the body, making it safe for implantation.

    To meet other medical needs, platinum can be formed into rods, wires, ribbons, sheets and micromachined parts. Further, it helps fight cancer in the drugs cisplatin and carboplatin, which are widely used to treat testicular cancer, as well as ovarian, breast and lung cancer tumors.

    Medical demand for platinum has increased in recent years, and is forecast to rise 4 percent to 320,000 ounces in 2025 and another 4 percent to 322,000 ounces in 2026.

    FAQs about platinum

    How much is platinum worth?

    In 2026, the price of platinum has spiked significantly as part of a precious metals bull market trading as high as US$2,900. In 2025, the PGM ranged between US$960 and US$1,900 per ounce.

    Although the industry is facing a growing supply deficit, it is also dealing with lagging demand. The shortfall in supply is related to a hangover from COVID-19 lockdowns, Russia’s war in Ukraine and ongoing electricity shortages and railway issues in the top platinum producing country South Africa. Russia typically ranks as the world’s second largest platinum-producing country.

    Meanwhile, economic pressures worldwide have weighed on demand for platinum from the automotive industry. However, the same economic challenges have led to less demand for electric vehicles, which don’t require platinum-laden catalytic converters.

    Which is more valuable, gold or platinum? Why?

    Platinum in general has historically traded on par or at a premium to gold, but since 2015 the two metals have diverged in price, with gold taking the high road. This split has been attributed to gold’s safe-haven status and platinum’s reliance on the industrial and jewelry markets, which don’t fare well in times of economic uncertainty.

    This has led to increasing demand for platinum jewelry as a cheaper alternative to gold jewelry.

    Although platinum is 30 times rarer than gold, much harder to mine and in high demand due to its important industrial uses, precious metal gold has long been valued as a form of currency and a store of wealth. The gold price is almost double the price of platinum in 2026.

    What’s the best investment, gold or platinum?

    Both gold and platinum have wealth-generating potential, but it’s important to determine which precious metals fit your investment strategy; consider looking at supply, demand and prices for each option before making a decision.

    To learn more, check out our article What is the Best Precious Metal to Invest In?

    Securities Disclosure: I, Melissa Pistilli, hold no direct investment interest in any company mentioned in this article.

    This post appeared first on investingnews.com

    Keep Reading